Business Context and Reporting Period
Creative Medical Technology Holdings, Inc. filed a Form 8-K Current Report on January 12, 2021. The registrant is incorporated in Nevada and maintains its principal executive offices in Phoenix, Arizona. The filing reports a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
This filing does not contain financial statements, revenue figures, profit data, cash flow information, margins, debt levels, or liquidity metrics. The document focuses exclusively on a regulatory milestone.
Material Changes
The primary material event reported is the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA). This application concerns the Company's ImmCelz® regenerative immunotherapy intended for the treatment of stroke.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future performance, or a discussion of specific risks and contingencies beyond the context of the IND submission. The event represents a procedural step in the drug development lifecycle.
Investor Verification Checklist
- Verify the status of the FDA review for the ImmCelz® IND application.
- Confirm the specific indications and trial design for the stroke treatment therapy.
- Review subsequent filings for any FDA responses, clinical hold notices, or trial initiation dates.
- Assess the Company's capital position in light of the costs associated with clinical trials, as this filing contains no liquidity data.